Sir Wes, Thx for sharing the company response with us. The reason for delaying the data release was self evident. But the emphasis on OBD is reassuring. It has been mentioned before in the last presentation that we would achieve OBD this year and begin PH2 trials at this level.
Sounds like the OBD has taken a lot longer to achieve than IMU was originally anticipating. Hence the source of so much frustration amongst shareholders. It might be frustrating but it is great news just the same. The absence of any toxicity will help hugely at the FDA. And will drive a lot more value for shareholders.
Meanwhile we wait know that our Data Cuts are coming, without any surprise toxicity issues. We already know from the Cholangio Fast Track news that we have efficacy.
If you’re not an impatient bedwetter it’s all good here. Great science, sufficient funding and high quality scientific management.
IMU Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)